A to Z Summary Results - Patient Decision Aids - Ottawa Hospital Research Institute 


Patient Decision Aid Summary

Title Adjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer
To access it View the patient decision aid on the developer website
Audience Women who are post-menopausal with hormone receptor-positive (ER+ and/or PR+) breast cancer considering adjuvant endocrine therapy after having surgery, radiation, and/or chemotherapy.
Options included Take tamoxifen.
Take an aromatase inhibitor.
Take tamoxifen first, then switch to an aromatase inhibitor.
Year of last update or review 2018
Format paper, PDF
Developer American Society of Clinical Oncology (ASCO)
Where was it developed? www.asco.org/guidelines, guidelines@asco.org
American Society of Clinical Oncology
US
Health condition Breast Cancer
Language English
Based on 2025 IPDAS criteria (International Patient Decision Aid Standards) this patient decision aid (and/or supporting materials) meets:
6 out of 7 IPDAS Qualifying criteria to be defined as a patient decision aid
6 out of 7 IPDAS Essential criteria to lower the risk of making a biased decision
Not applicable: Other IPDAS Essential criteria for patient decision aids about screening or testing
View IPDAS criteria details.

Last modified: 2025-07-29.